著者

浜崎 智仁 糸村 美保

出版者

日本脂質栄養学会

雑誌

脂質栄養学 (ISSN:13434594)

巻号頁・発行日

vol.19, no.1, pp.59-63, 2010 (Released:2010-05-01)

参考文献数

10

被引用文献数

1

---

The cholesterol hypothesis that intake of saturated fatty acids increases blood cholesterol levels, which in turn increases the incidence of coronary heart disease (CHD), has hardly been proved. Even the most famous intervention study in Finland (Finnish Mental Hospital Study) was questionable; it must have been very difficult to diagnose CHD in heavily sedated patients without bias. However, because diabetes mellitus (DM) is one of the major risk factors of myocardial infarction, diabetologists adopted the hypothesis above to reduce CHD incidence and educated DM patients not to eat much land animals’ meat and their fat, which means high-carbohydrate diets. Unfortunately the more carbohydrate people eat, the higher blood glucose and insulin levels. In fact, if DM patients are treated with low-carbohydrate diets, hemoglobin A1c levels markedly drop. Because insulin levels are also reduced, body weight is reduced too. (Insulin is probably the most powerful agent for fattening.) The prevailing idea that low-fat is good for you does not hold true anymore. The exploding number of obese and diabetic patients in the US was the most horrible example of iatrogenic disease in the last century.

著者

浜崎 智仁 奥山 治美 大櫛 陽一

出版者

日本脂質栄養学会

雑誌

脂質栄養学 (ISSN:13434594)

巻号頁・発行日

vol.21, no.1, pp.77-87, 2012 (Released:2012-04-29)

参考文献数

27

被引用文献数

1 1

---

ファルマシアの2011年6月号に上島弘嗣氏の話題1)が掲載されており、我々の「コレステロールは高いほうが長生きする」の理論の“誤り”について解説している(引用符号は筆者らによる).小論では、上島氏の指摘に関し、その問題点を取り上げ,反論する.なお、小論は本来2011年に発表すべく努力してきたが、ファルマシアが掲載を認めなかったため、発表が遅れた。

著者

浜崎 智仁

出版者

日本脂質栄養学会

雑誌

脂質栄養学 (ISSN:13434594)

巻号頁・発行日

vol.20, no.1, pp.47-58, 2011 (Released:2011-05-01)

参考文献数

28

---

I emphasize the importance of conflict of interest and implications of Big Pharma-assisted clinical trials when discussing the effects of cholesterol-lowering medicines. The situation around papers on clinical trials has changed since EU Clinical Trial Directive took effect. Trials in which cholesterol levels were lowered or more lowered with aggressive treatment have shown no significant beneficial effects except for few exceptions after the Directive. I also show some other aspects of cholesterol that have rarely (or never) been discussed in Japan. For example; 1. The LDL-cholesterol levels in patients with familial hypercholesterolemia (FH) who have already suffered from coronary heart disease (CHD) are not higher than in FH patients without CHD. 2. LDL and other lipoproteins serve as a non-specific natural defense against bacteria and virus. 3. By understanding that LDL-cholesterol is not bad for your health, we can enter new stages of lipid nutrition. The intake of saturated fat does not increase cardiovascular death rates in Japan.

著者

奥山 治美 浜崎 智仁 大櫛 陽一 浜 六郎 内野 元 渡邊 浩幸 橋本 道男

出版者

日本脂質栄養学会

雑誌

脂質栄養学 (ISSN:13434594)

巻号頁・発行日

vol.22, no.2, pp.173-186, 2013 (Released:2013-10-01)

参考文献数

60

被引用文献数

1 1

---

Statins have been recognized clinically to raise blood glucose and glycated protein (HbA1c) levels enhancing the development of insulin resistance. However, most clinicians appear to adopt the interpretation that the benefit (prevention of CHD) outweighs the risk (new-onset of diabetes mellitus). Consistently, "Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases 2012" recommends diabetics to maintain LDL-C levels below 120 mg/dL; 40 mg/dL lower than the value for those without risky complications. This recommendation necessitates many diabetics to use statins. However, we pointed out that statins exhibited no significant benefit for the prevention of CHD in the trials performed by scientists independent of industries after 2004, when a new regulation on clinical trials took effect in EU (Cholesterol Guidelines for Longevity, 2010). Here, we reviewed clinical evidence that statins could induce diabetes mellitus, and biochemical evidence that statins are toxic to mitochondria; they suppress electron transport and ATP generation through decreased prenyl-intermediate levels. They also inhibit seleno-protein synthesis and dolichol-mediated glycation of insulin receptor leading to insulin resistance and cardiac failure, similarly to the case of Se-deficiency. These mechanisms of statin actions are consistent with clinically observed decreases in blood ketone body, mitochondrial dysfunctions and enhanced glucose intolerance. Based on these lines of evidence, we urgently propose that statins are contraindicant to diabetics and their prescription should be restricted to special cases* for which medical doctors rationally decide to be necessary.

著者

浜崎 智仁 奥山 治美 浜 六郎 大櫛 陽一

出版者

日本脂質栄養学会

雑誌

脂質栄養学 (ISSN:13434594)

巻号頁・発行日

vol.23, no.1, pp.71-78, 2014 (Released:2014-05-01)

参考文献数

8

被引用文献数

1

---

The risk chart of NIPPON DATA80 showing the absolute mortality from coronary heart disease (CHD) is the only chart of this type widely used in the medical field in Japan. In this chart, there are 240 frames for men with casual blood glucose of ≥200 mg/dL (the right side of the chart); these frames are separated according to smoking status, age, systolic blood pressure, and total cholesterol. The absolute CHD mortality during 10 years in these 240 frames ranges from <0.5% to ≥10% (more than 20 times difference). However, we estimated that there were only 5 CHD deaths at most in these 240 diabetic frames during the study period of NIPPON DATA80. The left (non-diabetic; another 240 frames) part of the chart was adopted for the Guidelines by Japan Atherosclerosis Society after excluding 60 frames for those in their 70s (180 frames as a whole), but those 180 frames were estimated to have only 35 CHD deaths despite the risk difference being more than 10. Furthermore, statistical values such as p value and confidence interval were not found either in the paper introducing the risk chart or in the referred paper for methodology. We, therefore, could not statistically estimate appropriateness of the risk chart. In conclusion, the NIPPON DATA80 risk chart for CHD mortality is not suitable for guidelines or education.

著者

奥山 治美 浜崎 智仁

出版者

日本脂質栄養学会

雑誌

脂質栄養学 (ISSN:13434594)

巻号頁・発行日

vol.22, no.1, pp.25-34, 2013 (Released:2013-05-01)

参考文献数

11

---

Arachidonic acid (ARA) is converted to eicosanoids with diverse physiological activities, which are essential for the maintenance of growth and reproductive physiology of mammals. However, excessive and unbalanced productions of eicosanoids from ARA are known to be causative of inflammation-related diseases including cancer, atherosclerotic diseases and allergic diseases, which are currently prevailing in the elderly in Japan. Omega 3 fatty acids can suppress excessive productions of eicosanoids from ARA, thereby serving to prevent these diseases. These interpretations are based on the results from nutritional, pharmacological and biotechnological studies performed worldwide. Therefore, it was a big surprise for us when a leading Japanese food company began to sell an ARA-containing supplement. With a Health and Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare, Japan, members of the committee of Japan Society for Lipid Nutrition performed a series of research on the safety and efficacy of ARA containing microbial oil to find little evidence to support the health benefits. Moreover, teratogenicity in the eye of a mouse strain was noted at 0.6 energy % ARA, together with cancer promoting activities, which are crucial as a supplement for elderly people. These safety issues need to be solved before supplementing humans with the ARA oil.

著者

浜崎 智仁 奥山 治美 大櫛 陽一 浜 六郎

出版者

日本脂質栄養学会

雑誌

脂質栄養学 (ISSN:13434594)

巻号頁・発行日

vol.22, no.1, pp.69-76, 2013 (Released:2013-05-01)

---

On September 8, 2012, the panel discussion “The Rethinking of Cholesterol Issues” was held in Sagamihara City, Japan. This paper is the summary of that panel discussion. Four discussants expressed their skeptical views against the cholesterol hypothesis. The whole discussion will be freely seen on the net. Also a similar editorial written by the four discussants will be published in English (Ann Nutr Metab 2013;62:32-36, a free PDF file is already available on the internet). Because Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012 (JASG 2012) has recently been published, the main part of this paper is focused on serious flaws found in JASG 2012. Dr Harumi Okuyama discusses the differences between JASG 2012 and our guidelines indicating that high cholesterol levels are a good index of longevity; the most important point is that the statin trials that have been performed after 2004, when the new EU law regulating clinical trials became in effect, are all negative. Dr Yoichi Ogushi claims that JASG 2012 intentionally omits some good aspects of cholesterol; cholesterol is a negative risk factor of stroke. His own data also show that cholesterol is good for stroke. He also claims that to properly treat patients with diabetes, we need to reject the cholesterol hypothesis and to reduce carbohydrate rather than cholesterol. Dr Tomohito Hamazaki points out unforgivable flaws in JASG 2012. It does not disclose any COI. It does not contain any relationship between cholesterol levels and all-cause mortality in Japan. Pharmaceutical companies spend 600 billion yen (7 billion US$) per year for advertisement in Japan. This works as “devil’s insurance” (withdrawal of advertisement is a real threat to the mass media). The last discussant, Dr Rokuro Hama, explains the mistake made by JAS (liver disease causes both death and depression of cholesterol levels, and low cholesterol levels are not the cause of death). Hepatitis C virus (HCV) enters hepatic cells via LDL receptors, and low cholesterol levels are one of the major risk factors of HCV infection and chronic hepatitis. Hence, death from liver disease could be the result of low cholesterol levels.

著者

浜崎 智仁 奥山 治美

出版者

日本脂質栄養学会

雑誌

脂質栄養学 (ISSN:13434594)

巻号頁・発行日

vol.24, no.1, pp.69-70, 2015

---

not provided

著者

浜崎 景 浜崎 智仁 稲寺 秀邦

出版者

日本静脈経腸栄養学会

雑誌

静脈経腸栄養 (ISSN:13444980)

巻号頁・発行日

vol.28, no.4, pp.967-971, 2013 (Released:2013-08-23)

参考文献数

33

---

気分障害(うつ病・双極性障害)の患者数が統計上明らかに増えており、90年代には40万人程度であったのが、現在では優に100万人を超えている。様々な要因が言われているが、我々はひょっとして食事の変化すなわち多価不飽和脂肪酸のω6:ω3比のアンバランスも関与しているのではないかと考えている。というのも、今までの様々な疫学調査や臨床試験の報告より、ω3系多価不飽和脂肪酸(以下ω3)が気分障害に関与していることがわかってきたからである。今のところ精神疾患の中でも特にうつ病に対して効果がありそうだが、本稿ではこの分野に関する海外からの疫学調査や臨床試験の報告を紹介したいと思う。

著者

稲寺 秀邦 浜崎 智仁

出版者

一般社団法人日本衛生学会

雑誌

日本衛生学雑誌 (ISSN:00215082)

巻号頁・発行日

vol.65, no.4, pp.506-515, 2010 (Released:2010-09-25)

参考文献数

57

被引用文献数

2 2

---

In 2007, the Japan Atherosclerosis Society published the Guidelines for prevention of atherosclerotic cardiovascular diseases. However, the guidelines have several flaws with regard to the cutoff level of serum low-density lipoprotein cholesterol (LDL-C). First, LDL-C level is used instead of serum total cholesterol (TC) level in the guidelines. In this case, they must show at least some basic data on the relationship between LDL-C level and mortality or morbidity from coronary heart disease (CHD). Second, it was recommended that the LDL-C level be below 140 mg/dL or 3.6 mmol/L (corresponding to a TC level of 220 mg/dL or 5.7 mmol/L, respectively). These levels are unreasonable considering that the TC levels of 240–260 mg/dL are optimal in terms of all-cause mortality for the Japanese population. Third, although there are big differences in mortality and morbidity from CHD between sexes, they discussed the matter without considering these differences. Last but not least, the conflict of interest of the editors of the guidelines has never been disclosed. The Japanese population has a lower CHD mortality and incidence than populations from other industrialized countries despite an increase in serum TC level in the former. In populations with a markedly lower coronary mortality or morbidity such as the Japanese population, it is still important to determine the optimal cutoff level of LDL-C to prevent the development of CHD and other atherosclerotic diseases.

著者

奥山 治美 浜 六郎 大櫛 陽一 浜崎 智仁 内野 元

出版者

日本脂質栄養学会

雑誌

脂質栄養学 (ISSN:13434594)

巻号頁・発行日

vol.27, no.1, pp.30-38, 2018 (Released:2018-07-16)

---

An open-label, randomized controlled trial in type 2 diabetics with hypertension, dyslipidemia, or both was reported (J-DOIT3 study).The participants were randomly assigned to receive conventional or intensive therapy with respect to HbA1c, blood pressure and LDL-C (n=1,271 in each group),and were followed for 8.5 years at 81 clinical sites. Both the participants and doctors in charge were aware of the group assigned. The experimental design was essentially as recommended in the [Comprehensive risk management chart for the prevention of cerebro- and cardiovascular diseases 2015] from the Joint Committee consisted of 13 internal medicine-related societies in Japan, and the Japan Atherosclerotic Society Guidelines 2017. Therefore, the conclusion from the J-DOIT3 study is expected in medical field to affect the current and future medications for the prevention of atherosclerotic cerebro- and cardiovascular diseases (ASCVD).While analyzing the results of this study,we encountered serious problems associated with the methodology, logics and its interpretations, which were summarized in this review. The follow-up study appears to be in progress as described in the Discussion, but we interpret that the intensive therapy used in the J-DOIT3 study is risky in view of currently available evidence. We propose the authors of the study to let the participants know of the results on its objective endpoint, and newly obtain Informed Consents including the potential risks of the intensive intervention based on the progress in this field after the start of this study.

著者

大櫛 陽一 浜 六郎 浜崎 智仁 内野 元

出版者

日本脂質栄養学会

雑誌

脂質栄養学 (ISSN:13434594)

巻号頁・発行日

vol.27, no.1, pp.39-47, 2018 (Released:2018-07-16)

---

A nationwide multicenter randomized controlled study (JDCS) was performed in type-2 diabetes patients. The conventional (CON) group received usual care including anti-diabetic, anti-hypertensive and anti-hyperlipidemic agents to maintain their targeted levels, and the intervention (INT) group additionally received intensive education on lifestyle modifications and adherence to treatment by telephone counselling and at each time outpatient clinic visit for 8 years. The JDCS appears to be based on an assumption that usual treatment of diabetes is appropriate for the prevention of diabetes complications, and that the lack of patients’ compliance is the major cause of unsuccessful treatments. No significant differences between the two groups were found in most of the test results (BMI, blood pressure, fasting glucose level, TC, HDL, lipoprotein-a), use of agents, life style (energy intake, smoking and alcohol intake) at 4 years of intervention. The exercise level was higher at 5 years of intervention, and triglyceride level was lower at 8 years. The incidence of coronary heart disease, retinopathy and neuropathy did not differ significantly between the two groups, but stroke incidence was lower in the INT group. We conducted new analyses on the changes of some explanatory variables in each group. The proportion of participants with pharmacological treatment including insulin significantly increased in both groups except sulfonylureas which about 60% of the participants used at the baseline. On the other hand, those without pharmacological treatment decreased from 19% to 4% in both groups. These indicate that both groups failed in diabetes treatment together. As for the exercise and the smoking cessation, these may prevent stroke, but do not contribute to improvement of diabetes. It is not convincing enough for us to support the validity of publicizing the treatment of diabetes patients used in the JDCS study performed at 59 universities and general hospitals in Japan.

著者

奥山 治美 笠本 進一 浜崎 智仁

出版者

日本脂質栄養学会

雑誌

脂質栄養学 (ISSN:13434594)

巻号頁・発行日

vol.27, no.1, pp.21-29, 2018-03-31 (Released:2018-07-16)

---

The Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases (JASGL) were based on “the lower, the better” hypothesis. However, we published Cholesterol Guidelines for Longevity 2010 based on the fact that cholesterol levels are inversely associated with all-cause mortality among general populations aged at 40 years and over. Here, we summarized the mechanisms of atherogenesis caused by statins and some types of vegetable oils with strokestimulating activity in the rat; they inhibit the VK1-VK2- osteocalcin target organs link, leading to artery calcification and lifestyle-related diseases. The mainstay of JASGL 2017 is the Suita study published in 2014, which is much smaller than the previous epidemiological study, NIPPONDATA 80, for JASGL 2012. Besides, the total and cardiovascular mortality of the study has not been published yet. We found some terrible mathematical errors that cannot be simple calculation mistakes. For example, deleting some study subjects actually increased the number of male participants instead. It is likely that no consistent epidemiological studies are available any more to JAS to protect their cholesterol hypothesis. JASGL 2017 calculated risk of coronary artery disease (CAD) in Japan where the incidence is very low. Then the story was fabricated to protect their notion that even the group with a very low risk in the world standard was classified as middle to high risk groups of CAD, which can lead to unnecessary medication. The GLs are disguised as those based on the cholesterol hypothesis; actually it became very clear that they are simply selling tools for statins.

著者

浜崎 景 浜崎 智仁 稲寺 秀邦

出版者

一般社団法人 日本心身医学会

雑誌

心身医学 (ISSN:03850307)

巻号頁・発行日

vol.54, no.9, pp.842-848, 2014-09-01 (Released:2017-08-01)

---

ω3系多価不飽和脂肪酸(以下,ω3)は,1970年頃から心筋梗塞などの動脈硬化症に対する予防効果を期待され,さまざまな疫学調査や臨床試験が行われてきた.それ以降ω3に関する論文数は右肩上がりに増加しており(Fig.1),1980年頃より精神疾患に関する疫学調査が報告され,2000年頃から精神疾患患者を対象とした臨床試験が多く行われるようになってきた.これまでのメタ解析の結果をみると,精神疾患の中でも特にうつ病に効果がみられることが示唆されている.現在では日本での気分障害の患者は100万人を超えていると推測されており,ω3が栄養学的な観点から治療の一助になる可能性もある.本稿ではわれわれが得た知見を紹介するとともに,この分野に関する海外からの疫学調査や臨床試験の報告を紹介する.

著者

奥山 治美 浜崎 智仁 大櫛 陽一

出版者

日本脂質栄養学会

雑誌

脂質栄養学 (ISSN:13434594)

巻号頁・発行日

vol.23, no.1, pp.79-88, 2014 (Released:2014-05-01)

参考文献数

13

被引用文献数

1

---

Previous cholesterol guidelines for the prevention of CHD were based on "the lower, the better" hypothesis, setting upper LDL-C limits and treating patients to maintain their cholesterol levels below the targets, as seen in the ATP 3 issued from the National Heart, Lung, and Blood Institute (NHLBI) and that issued from the Japan Atherosclerosis Society (JAS GL). We published a new cholesterol guideline for longevity (JSLN GL 2010), in which evidence was presented that a high cholesterol level is not a causative factor of CHD but is a predictor of longevity among general populations over 40-50 years of age. Recently, a long-waited revision of the ATP 3 was published from the NHLBI in conjunction with the American College of Cardiology and the American Heart Association (ACC/AHA GL 2013), in which "setting targets to treating patients with statins" and "the lower, the better hypothesis" were abandoned because of the lack of clinical evidence. However, both the JAS GL 2012 and ACC/AHA GL 2013 brought about estimated 10-year CHD (ASCVD) risk mainly based on NIPPON DATA 80 and NHLBI-supported studies, respectively, resulting in increased estimated number of subjects to be treated with statins. Here, we point out that the estimated 10-year risks are not usable because they are not evidence-based. Moreover, we summarize biochemical mechanisms underlying the statin actions to increase heart failure, diabetes mellitus and other diseases after long-term treatments. The cases for which statins, all mitochondrion-toxic, are applicable should be extremely restricted.

著者

小沢 昭夫 高柳 香都子 藤田 孝夫 平井 愛山 浜崎 智仁 寺野 隆 田村 泰 熊谷 朗

出版者

公益社団法人日本分析化学会

雑誌

分析化学 (ISSN:05251931)

巻号頁・発行日

vol.31, no.2, pp.87-91, 1982-02-05

被引用文献数

8 25

---

エスキモー人の疫学調査により魚脂中に多く含まれるω-3の高級多価不飽和脂肪酸の抗血栓,抗動脈硬化作用が注目されている.ヒト血しょう総譜質中の高級脂肪酸を精度よく測定するためにキャピラリーカラムを装着したガスクロマトグラフを用い血しょうよりFolchらの方法で抽出しBF_<-3>メタノールでエステル化した試料を分離分析したところ良好な成績が得られた.本法での抽出操作を含めた再現性はアラキドン酸,エイコサペンタエン酸,ドコサヘキサエン酸のいずれについても5%以下と良好で各各のメチルエステルを用いて得られた添加回収率もほぽ100%と良好な値を示した.又検量線もいずれの脂肪酸について良好な成績が得られ,又実際の実験食投与の健常人においても有意の脂肪酸の変動が認められたことから本法は血しょう総脂質中の高級脂肪酸の定量法の一つとして有用と考えられる.